H35.30 H35.0
Conditions
Interventions
Group 1: Single arm study design
Overview of Study Design
This is a non-interventional, multicenter, cross-sectional study, to collect data on treatment adherence and persistence, as well as reasons
Sponsors
F. Hoffmann-La Roche Ltd
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The patient has been diagnosed with nAMD and/or DME The patient is at least 18 years of age (DME)/ the patient is at least 50 years of age (nAMD) The patient has started IVT with anti-VEGF therapy in routine clinical practice =5 years ago The patient is currently receiving (or received at the time of last injection) an anti-VEGF agent approved in Germany for the respective indication (nAMD/DME) The patient receives all care in relation to their eye disease at one center/practice (no referral by another practice/center) To the knowledge of the treating physician, the patient has not previously received and is not currently receiving IVT with anti-VEGF therapy at another center/practice The patient is capable of participating in a 45-minute telephone interview in German language Basic clinical information about the patient and his/her care is available in the patient charts (minimum 6-month medical records).
Exclusion criteria
Exclusion criteria: There are no explicit exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe barriers to IVT adherence experienced by nAMD and DME patients and to investigate and quantify whether injection frequency exert an influence on patients’ adherence and persistence to IVT. To elicit reasons for non-persistence | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore physician’s awareness and understanding of adherence and persistence and to shine light on the practical hurdles faced by treating ophthalmologists. | — |
Countries
Germany
Contacts
Public ContactMarco Ghiani
Ingress-Health HWM GmbH - A Cytel Company
Outcome results
None listed